PE20121542A1 - Moleculas de anticuerpo anti-gcc y composiciones y metodos relacionados - Google Patents
Moleculas de anticuerpo anti-gcc y composiciones y metodos relacionadosInfo
- Publication number
- PE20121542A1 PE20121542A1 PE2012000399A PE2012000399A PE20121542A1 PE 20121542 A1 PE20121542 A1 PE 20121542A1 PE 2012000399 A PE2012000399 A PE 2012000399A PE 2012000399 A PE2012000399 A PE 2012000399A PE 20121542 A1 PE20121542 A1 PE 20121542A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- cdr1
- cdr2
- cdr3
- amino acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 abstract 5
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 101710095468 Cyclase Proteins 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Radiology & Medical Imaging (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Inorganic Chemistry (AREA)
Abstract
SE REFIERE A MOLECULAS DE ANTICUERPOS DEL ISOTIPO IgG1, QUE SE UNE A LA GUANILO CICLASA HUMANA (GCC), DICHAS MOLECULAS DE ANTICUERPOS PUEDEN SER: A) 3G1 QUE COMPRENDE UNA REGION VARIABLE DE CADENA PESADA DE SECUENCIAS DE AMINOACIDOS DE SEQ ID NO. 2, CON CDR1 DE SEQ ID NO. 58, CDR2 DE SEQ ID. NO. 60 Y CDR3 DE SEQ ID. NO. 62 Y UNA REGION VARIABLE DE CADENA LIVIANA DE SECUENCIA DE AMINOACIDOS DE SEQ ID NO. 4, CON CDR1 DE SEQ ID NO. 64, CDR2 DE SEQ ID. NO. 66 Y CDR3 DE SEQ ID. NO. 68; B) 5F9 QUE COMPRENDE UNA REGION VARIABLE DE CADENA PESADA DE SECUENCIAS DE AMINOACIDOS DE SEQ ID NO. 18, CON CDR1 DE SEQ ID NO. 106, CDR2 DE SEQ ID. NO. 108 Y CDR3 DE SEQ ID. NO. 110 Y UNA REGION VARIABLE DE CADENA LIVIANA DE SECUENCIA DE AMINOACIDOS DE SEQ ID NO. 20, CON CDR1 DE SEQ ID NO. 112, CDR2 DE SEQ ID. NO. 114 Y CDR3 DE SEQ ID. NO. 116 Y C) Ab-229 QUE COMPRENDE UNA REGION VARIABLE DE CADENA PESADA DE SECUENCIAS DE AMINOACIDOS DE SEQ ID NO. 46, CON CDR1 DE SEQ ID NO. 190, CDR2 DE SEQ ID. NO. 192 Y CDR3 DE SEQ ID. NO. 194 Y UNA REGION VARIABLE DE CADENA LIVIANA DE SECUENCIA DE AMINOACIDOS DE SEQ ID NO. 48, CON CDR1 DE SEQ ID NO. 196, CDR2 DE SEQ ID. NO. 198 Y CDR3 DE SEQ ID. NO. 200. REFERIDO ADEMAS A UN INMUNOCONJUGADO QUE COMPRENDE UN ANTICUERPO ANTI-GCC Y UNA MARCA O AGENTE TERAPEUTICO, UN METODO DE PRODUCCION Y UN VECTOR. DICHAS MOLECULAS DE ANTICUERPO SON UTILES PARA EL TRATAMIENTO DE CANCER DE COLON
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25447409P | 2009-10-23 | 2009-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20121542A1 true PE20121542A1 (es) | 2012-12-06 |
Family
ID=43900696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2012000399A PE20121542A1 (es) | 2009-10-23 | 2010-10-22 | Moleculas de anticuerpo anti-gcc y composiciones y metodos relacionados |
Country Status (32)
Country | Link |
---|---|
US (3) | US8785600B2 (es) |
EP (2) | EP2490720B1 (es) |
JP (2) | JP5925684B2 (es) |
KR (2) | KR101834890B1 (es) |
CN (3) | CN104447996A (es) |
AR (1) | AR078751A1 (es) |
AU (1) | AU2010310545C1 (es) |
BR (1) | BR112012007523A2 (es) |
CA (2) | CA3031851C (es) |
CL (1) | CL2012000806A1 (es) |
CR (1) | CR20120124A (es) |
DO (1) | DOP2012000066A (es) |
EA (2) | EA030827B1 (es) |
EC (1) | ECSP12011761A (es) |
ES (1) | ES2788457T3 (es) |
GE (2) | GEP20166504B (es) |
IL (3) | IL218763A (es) |
IN (1) | IN2012DN02604A (es) |
MA (1) | MA33601B1 (es) |
MX (3) | MX2012003198A (es) |
MY (1) | MY173390A (es) |
NZ (2) | NZ598791A (es) |
PE (1) | PE20121542A1 (es) |
PH (1) | PH12019500438A1 (es) |
PL (1) | PL2490720T3 (es) |
SA (1) | SA110310795B1 (es) |
SG (3) | SG179567A1 (es) |
TN (1) | TN2012000122A1 (es) |
TW (2) | TWI583394B (es) |
UA (1) | UA108991C2 (es) |
WO (1) | WO2011050242A1 (es) |
ZA (1) | ZA201201944B (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002051438A2 (en) | 2000-12-22 | 2002-07-04 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of repulsive guidance molecule (rgm) and its modulators |
EP1928905B1 (de) | 2005-09-30 | 2015-04-15 | AbbVie Deutschland GmbH & Co KG | Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung |
EP2033971A1 (de) * | 2007-09-06 | 2009-03-11 | Abbott GmbH & Co. KG | Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung |
US8962803B2 (en) * | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
US8785600B2 (en) | 2009-10-23 | 2014-07-22 | Millennium Pharmaceuticals, Inc. | Anti-GCC antibody molecules and related compositions and methods |
BR112012013734A2 (pt) * | 2009-12-08 | 2017-01-10 | Abbott Gmbh & Co Kg | anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina. |
KR101844479B1 (ko) | 2011-11-17 | 2018-04-03 | 삼성전자주식회사 | 항 c-Met 항체 및 그의 용도 |
IL297229A (en) | 2012-01-27 | 2022-12-01 | Abbvie Inc | The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells |
NZ701601A (en) * | 2012-04-27 | 2016-09-30 | Millennium Pharm Inc | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
WO2014004376A2 (en) | 2012-06-26 | 2014-01-03 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
EP2961424A4 (en) * | 2013-02-28 | 2016-10-19 | Millennium Pharm Inc | ADMINISTRATION OF AN ANTI-GCC-ANTIBODY-ACTIVE CONJUGATE AND A DNA DAMAGING ACTIVE IN THE TREATMENT OF CANCER |
JP6847388B2 (ja) * | 2013-03-15 | 2021-03-31 | レゲネロン ファーマシューティカルス,インコーポレーテッド | 生物活性分子、そのコンジュゲート、及び治療用途 |
KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
JP2015209384A (ja) * | 2014-04-24 | 2015-11-24 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 医薬製剤 |
EP3411075A1 (en) * | 2016-02-05 | 2018-12-12 | Millennium Pharmaceuticals, Inc. | Gcc-targeted antibody-drug conjugates |
EP3988111A1 (en) | 2016-04-01 | 2022-04-27 | Innovative Cellular Therapeutics Holdings, Ltd. | Use of chimeric antigen receptor modified cells to treat cancer |
US10654934B2 (en) | 2016-04-01 | 2020-05-19 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
KR101928079B1 (ko) | 2016-12-12 | 2018-12-11 | 한화케미칼 주식회사 | 디시클로펜타디엔계 수지의 제조 방법 및 디시클로펜타디엔계 수지 |
CN116672463A (zh) * | 2017-02-17 | 2023-09-01 | 浙江特瑞思药业股份有限公司 | 靶向cd20抗体偶联药物的制备方法、抗体偶联药物及其用途 |
CN108452319A (zh) * | 2017-02-20 | 2018-08-28 | 浙江特瑞思药业股份有限公司 | 靶向cd20的抗体偶联药物制剂 |
EP3765078A4 (en) * | 2018-03-16 | 2021-12-22 | Thomas Jefferson University | CHIMERIC ANTI-GUCY2C ANTIGEN RECEPTOR COMPOSITIONS AND PROCEDURES |
KR20230146098A (ko) * | 2018-05-23 | 2023-10-18 | 화이자 인코포레이티드 | GUCY2c에 특이적인 항체 및 이의 용도 |
TW202108177A (zh) | 2019-05-10 | 2021-03-01 | 日商武田藥品工業股份有限公司 | 抗體藥物結合物 |
WO2021076559A1 (en) * | 2019-10-14 | 2021-04-22 | The Scripps Research Institute | Human broadly neutralizing antibodies against the membrane-proximal external region of hiv env for vaccine design and intervention |
AU2020475819A1 (en) * | 2019-11-07 | 2022-06-23 | Thomas Jefferson University | Anti-GUCY2C vaccines and vaccination |
WO2021205325A1 (en) * | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
US20210371492A1 (en) * | 2020-06-02 | 2021-12-02 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC Antibody and CAR thereof for Treating Digestive System Cancer |
TW202237639A (zh) * | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 鳥苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法 |
TW202237638A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法 |
IL305181A (en) | 2021-02-15 | 2023-10-01 | Takeda Pharmaceuticals Co | Cell therapy compositions and methods for modulating TGF-B signaling |
EP4299594A1 (en) * | 2021-04-07 | 2024-01-03 | Lg Chem, Ltd. | Gucy2c binding polypeptide and uses thereof |
CN115521379B (zh) * | 2021-07-16 | 2023-12-22 | 南京吉盛澳玛生物医药有限公司 | Pd-1抗体及其用途 |
WO2024067762A1 (en) * | 2022-09-28 | 2024-04-04 | Nanjing Legend Biotech Co., Ltd. | Antibody and chimeric antigen receptors targeting gcc and methods of use thereof |
WO2024109877A1 (en) * | 2022-11-23 | 2024-05-30 | Full-Life Technologies Hk Limited | Antibody specifically binding to gcc |
CN116535514B (zh) * | 2023-06-15 | 2024-02-02 | 上海斯丹赛生物技术有限公司 | 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用 |
Family Cites Families (179)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US35500A (en) | 1862-06-10 | Improvement in dampers | ||
US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4289747A (en) | 1978-12-26 | 1981-09-15 | E-Y Laboratories, Inc. | Immunological determination using lectin |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
GB8800077D0 (en) | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel chimeric antibodies |
JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル. モリソン,シェリー | ドメイン‐変性不変部を有する抗体 |
IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
JP3070763B2 (ja) | 1989-08-09 | 2000-07-31 | ロメッド インコーポレイティド | テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識 |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
US5237051A (en) * | 1990-12-06 | 1993-08-17 | Vanderbilt University | Purified enterotoxin receptor protein |
US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
EP0552108B1 (en) | 1992-01-17 | 1999-11-10 | Lakowicz, Joseph R. | Energy transfer phase-modulation fluoro-immunoassay |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
DE69331089T2 (de) | 1992-02-18 | 2002-07-18 | Otsuka Kagaku Kk | Beta-Laktam und Cepham Verbindungen und Ihre Herstellung |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
DK0656946T4 (da) | 1992-08-21 | 2010-07-26 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
DE69232604T2 (de) | 1992-11-04 | 2002-11-07 | City Of Hope Duarte | Antikörperkonstrukte |
US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
DK0804070T3 (da) | 1993-03-09 | 2000-08-07 | Genzyme Corp | Fremgangsmåde til isolering af proteiner fra mælk |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
JP4194113B2 (ja) * | 1993-10-26 | 2008-12-10 | トーマス・ジェファーソン・ユニバーシティ | 結腸直腸癌細胞に特異的に結合する組成物およびその使用方法 |
US7097839B1 (en) * | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
US5518888A (en) | 1993-10-26 | 1996-05-21 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
US5879656A (en) * | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
US5601990A (en) | 1994-09-13 | 1997-02-11 | Thomas Jefferson University | Methods of diagnosing colorectal tumors and metastasis thereof |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
US6455251B1 (en) | 1994-09-13 | 2002-09-24 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
PT871490E (pt) | 1995-12-22 | 2003-07-31 | Bristol Myers Squibb Co | Ligantes de hidrazona ramificada |
CA2254082C (en) | 1996-05-03 | 2012-09-11 | Thomas Jefferson University | Metastatic colorectal cancer vaccine |
WO1997042506A1 (en) | 1996-05-03 | 1997-11-13 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US6340463B1 (en) | 1996-08-14 | 2002-01-22 | Vanderbilt University | Identification of antigenic peptide sequences |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
GB9700154D0 (en) | 1997-01-07 | 1997-02-26 | Primapharma Ltd | Peptides |
WO1998036765A1 (en) | 1997-02-25 | 1998-08-27 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
US6120995A (en) * | 1997-08-07 | 2000-09-19 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
US6197582B1 (en) | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
US6696550B2 (en) * | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
ES2257094T3 (es) | 1998-11-03 | 2006-07-16 | Centocor, Inc. | Anticuerpos modificados y fragmentos de anticuerpo con duracion de actividad aumentada. |
US8092514B1 (en) | 1998-11-16 | 2012-01-10 | Boston Scientific Scimed, Inc. | Stretchable anti-buckling coiled-sheet stent |
EP1051432B1 (en) | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
US6132922A (en) | 1999-01-06 | 2000-10-17 | Advanced Color Technology, Inc. | Liquid developer for electrophotographic printing apparatus |
KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
US20040031072A1 (en) * | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
EP1101113A4 (en) * | 1999-06-09 | 2002-05-08 | Ljl Biosystems Inc | CELL SIGNALING TESTS |
US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
DE60032633T2 (de) | 1999-11-24 | 2007-10-04 | Immunogen Inc., Cambridge | Zytotoxische mittel, die taxane enthalten und ihre therapeutische anwendung |
FR2805994A1 (fr) | 2000-03-10 | 2001-09-14 | Agronomique Inst Nat Rech | Methode de detection de la guanylyl cyclase-c et son utilisation pour le diagnostic des tumeurs colorectales metastatiques |
DE60142228D1 (de) | 2000-03-27 | 2010-07-08 | Univ Jefferson | Zusammensetzungen und methoden zur identifizierung und zum targeting von krebszellen aus dem verdauungskanal |
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
ATE524195T1 (de) * | 2001-01-26 | 2011-09-15 | Inhibitex Inc | Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen |
ES2622468T3 (es) | 2001-03-29 | 2017-07-06 | Synergy Pharmaceuticals, Inc. | Agonistas del receptor de guanilato ciclasa para el tratamiento de inflamación tisular y carcinogénesis |
WO2002079235A2 (en) * | 2001-03-30 | 2002-10-10 | University Of Copenhagen | Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease |
UA83791C2 (ru) * | 2001-04-13 | 2008-08-26 | Байоджен Айдек Ма Инк. | Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1 |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
AU2002319544B2 (en) | 2001-08-10 | 2008-07-10 | Aberdeen University | Antigen binding domains from fish |
US7371849B2 (en) | 2001-09-13 | 2008-05-13 | Institute For Antibodies Co., Ltd. | Methods of constructing camel antibody libraries |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
AU2002337935B2 (en) | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US6924360B2 (en) * | 2001-12-28 | 2005-08-02 | Abgenix, Inc. | Antibodies against the MUC18 antigen |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20030186302A1 (en) * | 2002-03-29 | 2003-10-02 | Yixin Wang | Colorectal cancer diagnostics |
WO2004010957A2 (en) | 2002-07-31 | 2004-02-05 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
WO2004024750A2 (en) * | 2002-09-13 | 2004-03-25 | Dyax Corporation | Cd44-binding ligands |
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2004071436A2 (en) * | 2003-02-10 | 2004-08-26 | Thomas Jefferson University | The use of gcc ligands |
WO2004101790A1 (en) * | 2003-05-14 | 2004-11-25 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
AU2004259398A1 (en) * | 2003-06-27 | 2005-02-03 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
US7871610B2 (en) * | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
WO2005084390A2 (en) | 2004-03-02 | 2005-09-15 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
ES2549077T3 (es) | 2004-04-07 | 2015-10-22 | Genentech, Inc. | Espectrometría de masas de conjugados de anticuerpos |
US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
EP2722060A3 (en) | 2004-06-25 | 2015-01-07 | Thomas Jefferson University | Guanylyl cyclase C ligands |
ES2715776T3 (es) | 2004-11-12 | 2019-06-06 | Seattle Genetics Inc | Auristatinas que tienen una unidad de ácido aminobenzoico en el extremo N |
WO2006068953A2 (en) * | 2004-12-21 | 2006-06-29 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
ES2393885T7 (es) | 2007-06-04 | 2014-01-30 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
KR20150059813A (ko) | 2007-08-10 | 2015-06-02 | 센토코 오르토 바이오테크 인코포레이티드 | 질환 표시자로서의 면역글로불린 절단 단편, 및 그의 검출 및 결합을 위한 조성물 |
CA2695997C (en) * | 2007-08-10 | 2016-11-22 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
US7968687B2 (en) | 2007-10-19 | 2011-06-28 | Seattle Genetics, Inc. | CD19 binding agents and uses thereof |
CN101925612A (zh) | 2007-11-27 | 2010-12-22 | 维文蒂阿生物技术公司 | 针对癌相关的nfkbib变体的表位的抗体及其用途 |
RS51987B (en) | 2007-11-30 | 2012-02-29 | Genentech Inc. | VEGF POLYMORPHISMS AND ANTI-ANGIOGENESIC THERAPY |
CA2760050A1 (en) | 2008-05-13 | 2009-11-19 | Thomas Jefferson University | Guanylyl cyclase c qrt-pcr |
JP2011523662A (ja) | 2008-06-04 | 2011-08-18 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
US9090695B2 (en) | 2008-12-03 | 2015-07-28 | Morphosys Ag | Antibodies for guanylyl cyclase receptors |
ES2637174T3 (es) | 2009-02-12 | 2017-10-11 | Cell Signaling Technology, Inc. | Expresión de ROS mutante en el cáncer de hígado humano |
CA2752668A1 (en) | 2009-02-25 | 2010-09-02 | Diagnocure Inc. | Method for detecting metastasis of gi cancer |
EP2407786A4 (en) | 2009-03-12 | 2013-01-02 | Univ Kinki | METHOD FOR PREDICTING THE THERAPEUTIC EFFICACY OF CHEMOTHERAPY ON NON-SMALL CELL LUNG CANCER |
CA2801729A1 (en) | 2009-06-15 | 2010-12-23 | Thomas Jefferson University | Compositions for and methods of activating guanylyl cyclase c |
EP3444333A1 (en) | 2009-10-22 | 2019-02-20 | Thomas Jefferson University | Cell-based anti-cancer compositions and methods of making and using the same |
US8785600B2 (en) | 2009-10-23 | 2014-07-22 | Millennium Pharmaceuticals, Inc. | Anti-GCC antibody molecules and related compositions and methods |
WO2011150454A1 (en) | 2010-06-01 | 2011-12-08 | Monash University | ANTIBODIES DIRECTED TO THE UNPROCESSED RECEPTOR TYROSINE KINASE c-MET |
AU2011288354A1 (en) | 2010-08-13 | 2013-01-24 | F. Hoffmann-La Roche Ag | Neuropilin as a biomarker for bevacizumab combination therapies |
US20150086481A1 (en) * | 2011-07-28 | 2015-03-26 | Memorial Sloan-Kettering Cancer Center | Diagnosis and treatment of parkinson's disease |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
NZ701601A (en) | 2012-04-27 | 2016-09-30 | Millennium Pharm Inc | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
EP2961424A4 (en) | 2013-02-28 | 2016-10-19 | Millennium Pharm Inc | ADMINISTRATION OF AN ANTI-GCC-ANTIBODY-ACTIVE CONJUGATE AND A DNA DAMAGING ACTIVE IN THE TREATMENT OF CANCER |
JP2017503763A (ja) | 2013-12-03 | 2017-02-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Gcc発現細胞を撮像するための化合物及び組成物 |
EP3411075A1 (en) | 2016-02-05 | 2018-12-12 | Millennium Pharmaceuticals, Inc. | Gcc-targeted antibody-drug conjugates |
EP3988111A1 (en) | 2016-04-01 | 2022-04-27 | Innovative Cellular Therapeutics Holdings, Ltd. | Use of chimeric antigen receptor modified cells to treat cancer |
-
2010
- 2010-10-22 US US12/910,393 patent/US8785600B2/en active Active
- 2010-10-22 AR ARP100103895A patent/AR078751A1/es active IP Right Grant
- 2010-10-22 EP EP10825726.2A patent/EP2490720B1/en active Active
- 2010-10-22 EP EP19153014.6A patent/EP3520816B1/en active Active
- 2010-10-22 CA CA3031851A patent/CA3031851C/en not_active Expired - Fee Related
- 2010-10-22 GE GEAP201012649A patent/GEP20166504B/en unknown
- 2010-10-22 BR BR112012007523A patent/BR112012007523A2/pt not_active Application Discontinuation
- 2010-10-22 ES ES10825726T patent/ES2788457T3/es active Active
- 2010-10-22 JP JP2012535402A patent/JP5925684B2/ja active Active
- 2010-10-22 CN CN201410653631.3A patent/CN104447996A/zh active Pending
- 2010-10-22 CA CA2774032A patent/CA2774032C/en active Active
- 2010-10-22 MX MX2012003198A patent/MX2012003198A/es active IP Right Grant
- 2010-10-22 SG SG2012018735A patent/SG179567A1/en unknown
- 2010-10-22 NZ NZ598791A patent/NZ598791A/en unknown
- 2010-10-22 CN CN201910115045.6A patent/CN110054692A/zh active Pending
- 2010-10-22 PE PE2012000399A patent/PE20121542A1/es active IP Right Grant
- 2010-10-22 AU AU2010310545A patent/AU2010310545C1/en active Active
- 2010-10-22 WO PCT/US2010/053686 patent/WO2011050242A1/en active Application Filing
- 2010-10-22 NZ NZ623607A patent/NZ623607A/en unknown
- 2010-10-22 CN CN201080043591.0A patent/CN102573908B/zh active Active
- 2010-10-22 MY MYPI2012001461A patent/MY173390A/en unknown
- 2010-10-22 TW TW104108678A patent/TWI583394B/zh active
- 2010-10-22 TW TW099136206A patent/TWI483736B/zh active
- 2010-10-22 SG SG10201407757XA patent/SG10201407757XA/en unknown
- 2010-10-22 EA EA201270365A patent/EA030827B1/ru unknown
- 2010-10-22 GE GEAP201013723A patent/GEP20196956B/en unknown
- 2010-10-22 KR KR1020127008350A patent/KR101834890B1/ko active IP Right Grant
- 2010-10-22 SG SG10202011656XA patent/SG10202011656XA/en unknown
- 2010-10-22 EA EA201792376A patent/EA201792376A3/ru unknown
- 2010-10-22 KR KR1020177031272A patent/KR20170123723A/ko not_active Application Discontinuation
- 2010-10-22 IN IN2604DEN2012 patent/IN2012DN02604A/en unknown
- 2010-10-22 UA UAA201203867A patent/UA108991C2/uk unknown
- 2010-10-22 MX MX2014004519A patent/MX366890B/es unknown
- 2010-10-22 PL PL10825726T patent/PL2490720T3/pl unknown
- 2010-10-23 SA SA110310795A patent/SA110310795B1/ar unknown
-
2012
- 2012-03-14 DO DO2012000066A patent/DOP2012000066A/es unknown
- 2012-03-14 CR CR20120124A patent/CR20120124A/es unknown
- 2012-03-15 MX MX2019008956A patent/MX2019008956A/es unknown
- 2012-03-15 ZA ZA2012/01944A patent/ZA201201944B/en unknown
- 2012-03-19 TN TNP2012000122A patent/TN2012000122A1/en unknown
- 2012-03-20 IL IL218763A patent/IL218763A/en active IP Right Grant
- 2012-03-21 MA MA34712A patent/MA33601B1/fr unknown
- 2012-03-30 CL CL2012000806A patent/CL2012000806A1/es unknown
- 2012-03-30 EC ECSP12011761 patent/ECSP12011761A/es unknown
-
2014
- 2014-06-02 US US14/293,802 patent/US20140322233A1/en not_active Abandoned
-
2015
- 2015-11-04 JP JP2015216375A patent/JP2016028603A/ja active Pending
-
2016
- 2016-09-15 IL IL247842A patent/IL247842B/en active IP Right Grant
-
2018
- 2018-06-26 IL IL260285A patent/IL260285B/en active IP Right Grant
- 2018-07-06 US US16/029,101 patent/US10941211B2/en active Active
-
2019
- 2019-02-28 PH PH12019500438A patent/PH12019500438A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20121542A1 (es) | Moleculas de anticuerpo anti-gcc y composiciones y metodos relacionados | |
PE20110345A1 (es) | Anticuerpos contra la il17 humana | |
PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
PE20190353A1 (es) | Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos | |
PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
PE20140247A1 (es) | Anticuerpos anti-cd38 | |
PE20180926A1 (es) | Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos | |
PE20141017A1 (es) | Anticuerpos del cea | |
NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
AR105724A1 (es) | Anticuerpos anti-bcma (antígeno de maduración de células b), moléculas de unión a antígenos biespecifícas que se unen a bcma y cd3 (determinante agregado 3), y usos de éstas | |
PE20170912A1 (es) | Conjugados de anticuerpo-farmaco | |
AR091702A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
PE20131209A1 (es) | Anticuerpos anti-fap | |
PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
AR102698A1 (es) | Anticuerpos contra cd73 y sus usos | |
PE20190737A1 (es) | Anticuerpos anti-cd27 | |
PE20121649A1 (es) | Anticuerpos monoclonales frente a progastrina y sus usos | |
PE20170670A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
PE20140194A1 (es) | Agentes de union a cd33 | |
PE20160712A1 (es) | Anticuerpos e inmunoconjugados anti-cd33 | |
PE20121691A1 (es) | Formulacion de anticuerpos y regimenes terapeuticos | |
PE20130479A1 (es) | Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos | |
PE20142243A1 (es) | Anticuerpos que se unen a ox40 y sus usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |